Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06869252

Autologous Adipose Cells Therapy

Autologous Adipose Cell Therapy is a series of process designated to address the demerits of the traditional autologous fat grafting and dermal fillers, while enhancing the versatility and aesthetic outcomes. In this study, the goal is to evaluate the safety and efficacy of Autologous Adipose cell Therapy for skin rejuvenation and hair improvement in human application.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hair Loss/Baldness Alopecia Fine Lines Hair Diseases Hair Thinning Hypotrichosis Pathologic Processes Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Pigmentation Disorders Skin Diseases Skin Elasticity Skin Pigmentation Skin Texture Skin and Connective Tissue Diseases Volume Wrinkle Appearance

Age range

21 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

The Centre for Cosmetic Surgery & Medicine, Newark, Lewes, Delaware, United States

Loading trial locations.

About this study

Autologous fat grafting (AFG) and injection of dermal fillers are the most prevailing aesthetic procedures in the cosmetic field for skin rejuvenation and hair restoration. High degree of biocompatibility and biodegradability of dermal fillers contribute significantly to their effectiveness in skin rejuvenation and hair restoration; however, the results are typically not enduring. On the other hand, autologous fat grafting is increasingly recognized for its applications not only in skin rejuvenation, but also breast augmentation and the treatment of arthritis. Fat fillers are fully biocompatible to the recipient, due to the use of autologous cell, the effects generally persist longer than those achieved with dermal fillers. Nonetheless, unprocessed lipoaspirate collected through liposuction procedure has a heterogeneous composition, which potentially leads to uneven distribution of adipose tissu resulting in formation of lumps or nodules at the recipient's site. Volume retention following autologous fat grafting is not solely affected by the resorption rate of adipose cells, but also impacted by re-uptake rate of other components of lipoaspirate. Autologous Adipose Cell Therapy seeks to enhance the current autologous fat grafting by isolating early-stage adipose cells from lipoaspirate and optimizing the number of adipocytes cells within the fat filler through cell property of differentiation. The purpose of this study is to assess the safety, feasibility, and efficacy of Autologous Adipose Cell Therapy for skin rejuvenation and hair improvement in human subjects. The eligibility of participants who are interested in participating in this study will be determined based on the inclusion and exclusion criteria listed in the study protocol. The in-charge plastic surgeon will monitor and evaluate the treatment outcomes in participants over a six-months period after the administration of Autologous Adipose Cell Therapy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Outpatients who express interest in skin rejuvenation, and/or who are experiencing skin conditions, such as winkles, fine lines, loss of skin elasticity, skin pigmentation, scarring.
  • Outpatients who are experiencing hair loss or hair thinning
  • Provision of signed and dated informed consent form
  • Clearly stated willingness to comply with all the procedures of the study and availability of the study
  • Female and Male aged between 21 to 80 years old 6 Medical clearance by family doctor

Exclusion criteria

  • Pregnancy or lactation
  • Known allergic reaction to components of cell culture media
  • Chronic disease , e.g. cardiovascular disease, diabetes, chronic kidney disease, seizures
  • Chronic infections, e.g. skin fungi infection, psoriasis
  • Chronic wound healing
  • Currently taking hormone therapy
  • History of cancers and active cancers
  • Viral infection, e.g. HIV, hepatitis B, influenza, coronaviruses.

Treatment and study plan

Autologous Adipose Cells Therapy

Biological

Participants will receive Autologous Adipose Cells therapy treatment, and the safety and efficacy of the treatment will be monitored by the primary investigator up to 25 weeks.

Primary outcomes

  1. Outcome Comparison Survey

    Time frame: The end of the study (Week 20 to 25)

    30 people will be randomly selected to rank the level of improvement by comparing the images captured at pro and post-treatment from Imaging assessment.

    Scale of Improvement:

    • No Improvement(0%)
    • Minimal Improvement(1% - 25%)
    • Moderate Improvement(26% - 50%)
    • Significant Improvement(51% - 75%)
    • Major Improvement(76% - 100%)

  2. Participant Satisfaction Survey

    Time frame: From first post-treatment follow-up visit to the last follow-up visit at week 16 to week 25

    Participants will be requested to complete a list of questions related to their experience and satisfaction of autologous adipose cell therapy in each study visit for result evaluation.

    1-to-5 Scales:

    • 1 being "very poor" and 5 being "excellent"
    • 1 being "very dissatisfied" and 5 being "very satisfied"

  3. Imaging Assessment

    Time frame: From first pre-treatment visit to the last follow-up visit at week 16 to week 25

    Digital images of the target site will be captured for each participant both prior to and following autologous adipose cell therapy for the purpose of outcome evaluation. The comparison of pre- and post-treatment images will be utilized in the "Outcome Comparison Survey" and the "Visit Evaluation Report" to assess the degree of improvement, based on the established assessment parameters for Autologous Adipose Cell Therapy treatment.

  4. Case Report Form

    Time frame: The report will be completed at the end of the study (Week 20 to 25), but highlights would be recorded in this document during every visit.

    A comprehensive medical document will be prepared by the responsible plastic surgeon which outlines the key details of each stage of the treatment process and aspects based on each participant's case. This document will include a thorough description of the patient's presenting medical conditions, the surgical procedures performed, post-treatment progress, any adverse events that occurred, and the final outcomes.

  5. Visit Evaluation Report

    Time frame: From first post-treatment follow-up visit to the last follow-up visit at week 16 to week 25

    During each post-treatment visit, the responsible plastic surgeon will assess the treatment outcomes and evaluate the degree of improvement by comparing the pre-treatment image with the current post-treatment image.

    Scale of Improvement:

    • No Improvement(0%)
    • Minimal Improvement(1% - 25%)
    • Moderate Improvement(26% - 50%)
    • Significant Improvement(51% - 75%)
    • Major Improvement(76% - 100%)

    Assessment Parameters:

    Skin:

    • Radiance
    • Texture
    • Firmness
    • Wrinkles & Fine Lines
    • Spot Hyperpigmentation
    • Tone
    • Redness & Inflammation
    • Pore Size

    Hair:

    • Density
    • Thickness
    • Visual Appearance
    • Texture (Smoothness & Frizz Control)
    • Shine
    • Scalp Health

Study contacts

Contact information is provided by the study sponsor or research team.

Ankeet Dixit

CONTACT

[email protected]

813-992-2521

Wing Nam Fung

CONTACT

[email protected]

207-671-9370

Sponsors and collaborators

Lead sponsor

CERM INC.

Industry

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2026
First posted
Mar 11, 2025
Registry last updated
May 31, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.